Corcept Insider Sells Shares Following FDA Approval and $1.05 Billion Outlook
William Guyer, Corcept Therapeutics' chief development officer, sold 20,000 shares valued at $1.9 million on July 7, 2026, as reported in an SEC Form 4 filing. The transaction was executed under a Rule 10b5-1 trading plan established earlier and does not appear to signal immediate concern given the pre-scheduled nature of the sale.
Tickers: $CORT